W
WAVEMAN · COMPANY
LUCD · Lucid Diagnostics Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475
← ALL COMPANIES

LUCD

Lucid Diagnostics Inc.
MEDICAL DEVICES · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · CIK 0001799011
SEC FILINGS☆ WATCH
INSIDER NET · 180D
$245.0K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
1
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
83
13F, latest reported quarter
REVENUE GROWTH
+8.3%
XBRL, annual
NET MARGIN
-1232.7%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$245.0K over 180 days
more than 86% of Medical Devices
CONGRESS
no member of Congress has reported trading it
FUNDS
83 funds added or opened last quarter
more than 53% of Medical Devices
REVENUE
+8.3% year over year
more than 52% of Medical Devices
MARGIN
-1232.7% net margin
below 98% of Medical Devices
BUYBACKS
no share repurchases reported
SHORT
6.0% of shares outstanding short · 8.3 days to cover · settled 2026-07-31
more than 71% of Medical Devices
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
83 funds added or opened positions in the latest 13F quarter, of 117 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -22.7%
-22.7%12M
-32%-16%-1%+15%2025-092025-102025-122026-032026-052026-072026-09 2026-05-20 · Matheis Dennis bought $245.0K
INSIDER BUY
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders are net buyers of their own stock.
The record shows a net $245.0K bought by insiders over 180 days, 83 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
TMOPENROKBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDX
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Lucid Diagnostics Inc. insiders bought a net $245.0K of stock across 21 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER
FILED
SHARES
VALUE
Matheis Dennis
Director
BUY
2026-05-20
245,000.0
$245.0K
Matheis Dennis
Director
BUY
2025-08-20
100,000.0
$102.0K
Matheis Dennis
Director
BUY
2025-05-22
33,218.0
$43.8K
Matheis Dennis
Director
BUY
2025-05-22
33,218.0
$43.8K
Matheis Dennis
Director
BUY
2025-05-21
129,684.0
$171.2K
21 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 16 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Alyeska Investment Group, L.P.
8,856,844.0 sh
$9.5M
BlackRock, Inc.
8,373,117.0 sh
$9.0M
VANGUARD CAPITAL MANAGEMENT LLC
6,556,344.0 sh
$7.0M
Two Seas Capital LP
6,000,000.0 sh
$6.4M
MASTERS CAPITAL MANAGEMENT LLC
4,000,000.0 sh
$4.3M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
U.S. Small Cap Equity Fund
$159.7K POSITION · AS OF 2026-03-31
0.1%
U.S. Small Cap Equity Fund
$681.1K POSITION · AS OF 2026-04-30
0.1%
AQR Small Cap Momentum Style Fund
$73.9K POSITION · AS OF 2026-03-31
0.0%
iShares Micro-Cap ETF
$261.6K POSITION · AS OF 2026-03-31
0.0%
1290 VT Micro Cap Portfolio
$19.2K POSITION · AS OF 2026-03-31
0.0%
T. Rowe Price Small-Cap Index Fund
$17.7K POSITION · AS OF 2026-03-31
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 5 registered trials, 0 still enrolling or running — a status change here is dated weeks before the press release
5
Not applicable
0 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$4.7M$4.3M$2.4M$377.0K
GROSS PROFIT———$377.0K
OPERATING INCOME$-49.6M$-46.1M$-48.5M$-56.3M
NET INCOME$-58.0M$-45.5M$-52.7M$-56.2M
EPS (DILUTED)—-1.05-1.26-1.55
OPERATING CASH FLOW$-46.5M$-44.1M$-32.8M$-29.7M
CASH—$22.4M$18.9M$22.5M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-04 ALL SYSTEMS LIVE FOR MACHINES →